| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A birth cohort approach to understanding cystic fibrosis lung infections
|
Fischer, Anthony J.
|
|
|
23 |
1 |
p. 8-11
|
artikel
|
| 2 |
A discrete choice experiment to quantify the influence of trial features on the decision to participate in cystic fibrosis trials
|
Dobra, Rebecca
|
|
|
23 |
1 |
p. 73-79
|
artikel
|
| 3 |
A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI
|
Gill, Eliana R.
|
|
|
23 |
1 |
p. 161-164
|
artikel
|
| 4 |
ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis
|
Gilchrist, Francis J.
|
|
|
23 |
1 |
p. 80-86
|
artikel
|
| 5 |
Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver transplant
|
Tachtatzis, P
|
|
|
23 |
1 |
p. 99-102
|
artikel
|
| 6 |
Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor
|
Meltzer, Lisa J.
|
|
|
23 |
1 |
p. 132-136
|
artikel
|
| 7 |
Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort
|
Nielsen, Bibi Uhre
|
|
|
23 |
1 |
p. 103-108
|
artikel
|
| 8 |
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis
|
Donaldson, Scott H.
|
|
|
23 |
1 |
p. 155-160
|
artikel
|
| 9 |
Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis
|
Martin, Isaac
|
|
|
23 |
1 |
p. 109-111
|
artikel
|
| 10 |
Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor
|
McParland, Caoimhe
|
|
|
23 |
1 |
p. 38-40
|
artikel
|
| 11 |
Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study
|
Wiesel, Vered
|
|
|
23 |
1 |
p. 41-49
|
artikel
|
| 12 |
How representative are clinical trial cohorts of the general CF population? Implications for trial planning
|
Dobra, Rebecca
|
|
|
23 |
1 |
p. 68-72
|
artikel
|
| 13 |
Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review
|
Guenther, Emma L.
|
|
|
23 |
1 |
p. 32-37
|
artikel
|
| 14 |
Letter to the editor: Risk of false newborn screening after intra-uterine exposure to ETI
|
De Wachter, E
|
|
|
23 |
1 |
p. 176-177
|
artikel
|
| 15 |
Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact
|
VanDevanter, D.R.
|
|
|
23 |
1 |
p. 58-64
|
artikel
|
| 16 |
Neurovascular complications post bronchial artery embolisation in patients with cystic fibrosis. A 7-year single centre retrospective review
|
Sapru, Karuna
|
|
|
23 |
1 |
p. 165-168
|
artikel
|
| 17 |
News Article
|
|
|
|
23 |
1 |
p. 1-2
|
artikel
|
| 18 |
Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor
|
Mingora, Christina M.
|
|
|
23 |
1 |
p. 3-4
|
artikel
|
| 19 |
Omitting placebos from early-stage clinical trials of cystic fibrosis therapies
|
Simon, Richard H.
|
|
|
23 |
1 |
p. 65-67
|
artikel
|
| 20 |
Optimization of performance of Dutch newborn screening for cystic fibrosis
|
Bouva, MJ
|
|
|
23 |
1 |
p. 120-125
|
artikel
|
| 21 |
Pancreatic duct organoid swelling is chloride-dependent
|
O'Malley, Yunxia
|
|
|
23 |
1 |
p. 169-171
|
artikel
|
| 22 |
Pharmacy compounded pilocarpine: An adequate solution to overcome shortage of pilogel® discs for sweat testing in patients with cystic fibrosis
|
Mian, P.
|
|
|
23 |
1 |
p. 126-131
|
artikel
|
| 23 |
Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study
|
Martiniano, Stacey L.
|
|
|
23 |
1 |
p. 50-57
|
artikel
|
| 24 |
Reanalysis of N2-lung clearance index and the comparison to SF6-lung clearance index and magnetic resonance imaging
|
Steinke, Eva
|
|
|
23 |
1 |
p. 150-154
|
artikel
|
| 25 |
Regarding the article entitled “Standards for the care of people with cystic fibrosis: A timely and accurate diagnosis”
|
Zhang, Linjie
|
|
|
23 |
1 |
p. 172
|
artikel
|
| 26 |
Reply to the letter Regarding the article entitled “Standards for the care of people with CF: a timely and accurate diagnosis”
|
Castellani, C
|
|
|
23 |
1 |
p. 173
|
artikel
|
| 27 |
Restless legs syndrome is prevalent in adults with cystic fibrosis and impacts sleep quality
|
Bista, Sabin R.
|
|
|
23 |
1 |
p. 137-143
|
artikel
|
| 28 |
Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor
|
Wang, Angela
|
|
|
23 |
1 |
p. 91-98
|
artikel
|
| 29 |
Sleep breathing disorder frequency, risk factors, and treatment among adults with cystic fibrosis
|
Maqsood, Asma
|
|
|
23 |
1 |
p. 144-149
|
artikel
|
| 30 |
Standards for the care of people with cystic fibrosis; establishing and maintaining health
|
Southern, Kevin W
|
|
|
23 |
1 |
p. 12-28
|
artikel
|
| 31 |
Stepping up by stepping down
|
Kotkowski, Christine Bielick
|
|
|
23 |
1 |
p. 5-7
|
artikel
|
| 32 |
Sweat induction using Pilocarpine microneedle patches for sweat testing in healthy adults
|
Chen, Jonathan Yuxuan
|
|
|
23 |
1 |
p. 112-119
|
artikel
|
| 33 |
The prevalence of children in the UK Cystic Fibrosis Registry on long term anti-Pseudomonas aeruginosa (PA) inhaled antibiotics who become culture negative for PA and a survey of practice for discontinuing treatment
|
Gilchrist, FJ
|
|
|
23 |
1 |
p. 174-175
|
artikel
|
| 34 |
Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation
|
Manika, Katerina
|
|
|
23 |
1 |
p. 29-31
|
artikel
|
| 35 |
When is Burkholderia cepacia complex truly eradicated in adults with cystic fibrosis? A 20-year follow up study
|
Tewkesbury, Daniel H
|
|
|
23 |
1 |
p. 87-90
|
artikel
|
Tijdschrift beschrijving